Addex reports 2023 half year and second quarter financial results and provides corporate update

Adx71149 phase 2 e pilepsy c linical s tudy cohort 2 continues recruiting following the independent interim review committee (irc) recommendation indivior gabab pam collaboration extended to june 2024 with chf 2.7 million of committed research funding chf 7.2 m ($ 8.0 m) of cash and cash equivalents at june 3 0 , 2023 ad hoc announcement pursuant to art. 53 lr geneva, switzerland, august 10 , 202 3 - addex therapeutics (six: adxn and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year and second quarter financial results for the periods ended june 30, 2023 and provided a corporate update.
ADXN Ratings Summary
ADXN Quant Ranking